Xenon Pharmaceuticals (XENE) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q4 2024 value amounting to $1.4 million.
- Xenon Pharmaceuticals' Accumulated Depreciation & Amortization rose 34963.1% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year increase of 34963.1%. This contributed to the annual value of $1.4 million for FY2024, which is 34963.1% up from last year.
- Xenon Pharmaceuticals' Accumulated Depreciation & Amortization amounted to $1.4 million in Q4 2024, which was up 34963.1% from -$542000.0 recorded in Q4 2023.
- Over the past 5 years, Xenon Pharmaceuticals' Accumulated Depreciation & Amortization peaked at $5.1 million during Q4 2020, and registered a low of -$542000.0 during Q4 2023.
- For the 5-year period, Xenon Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $2.5 million, with its median value being $2.4 million (2022).
- In the last 5 years, Xenon Pharmaceuticals' Accumulated Depreciation & Amortization tumbled by 12238.74% in 2023 and then soared by 34963.1% in 2024.
- Over the past 5 years, Xenon Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $5.1 million in 2020, then dropped by 22.83% to $4.0 million in 2021, then plummeted by 38.83% to $2.4 million in 2022, then plummeted by 122.39% to -$542000.0 in 2023, then surged by 349.63% to $1.4 million in 2024.
- Its last three reported values are $1.4 million in Q4 2024, -$542000.0 for Q4 2023, and $2.4 million during Q4 2022.